ES2644857T3 - Derivados de pirazolindiona como inhibidores de la NADPH - Google Patents
Derivados de pirazolindiona como inhibidores de la NADPH Download PDFInfo
- Publication number
- ES2644857T3 ES2644857T3 ES10782688.5T ES10782688T ES2644857T3 ES 2644857 T3 ES2644857 T3 ES 2644857T3 ES 10782688 T ES10782688 T ES 10782688T ES 2644857 T3 ES2644857 T3 ES 2644857T3
- Authority
- ES
- Spain
- Prior art keywords
- administered
- derivatives
- pyrazolindione
- nadph
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Description
5
15
25
35
45
55
65
invención pueden también ser administrados en formas de liberación sostenida o de sistemas de administración de medicamentos de liberación sostenida. Una descripción de los materiales representativos de liberación sostenida puede ser encontrada también en los materiales incluidos en Remington’s Pharmaceutical Sciences.
Vía de administración
Las composiciones de esta invención pueden administrarse en cualquier forma, incluyendo, pero no limitándose a, por vía oral, vía parenteral, vía sublingual, vía transdérmica, vía rectal, vía transmucosal, por vía tópica, por inhalación, a través de administración bucal o intranasal, o combinaciones de las mismas. La administración parenteral incluye, pero no está limitada a la vía intravenosa, intraarterial, intraperitoneal, subcutánea, intramuscular, intratecal e intraarticular. Las composiciones de esta invención también pueden ser administradas en la forma de un implante, que permite la liberación lenta de las composiciones, así como una infusión intravenosa lenta controlada. En una realización preferente, los derivados de pirazolindiona de acuerdo con la invención son administrados por vía intravenosa o subcutáneamente.
Esta invención está además ilustrada por los siguientes ejemplos que no se intenta que limiten el alcance de la invención de ninguna manera.
La dosificación administrada, como simples o múltiples dosis, a un individuo variará dependiendo de una variedad de factores, incluyendo las propiedades farmacocinéticas, las condiciones del paciente y sus características (sexo, edad, peso corporal, salud, tamaño), extensión de los síntomas, otros tratamientos coincidentes, la frecuencia del tratamiento y el efecto deseado.
Combinación
De acuerdo con una realización de la invención, los compuestos de acuerdo con la invención y las formulaciones farmacéuticas de los mismos pueden ser administrados solos o en combinación con un co-agente útil en el tratamiento del cáncer, tal como las sustancias utilizadas en la quimioterapia convencional dirigidas contra los tumores sólidos y para el control del establecimiento de metástasis o las sustancias utilizadas en hormonoterapia o cualquier otra molécula que actúa mediante la muerte celular programada activada es decir, por ejemplo un coagente seleccionados entre la categoría de los fármacos que detienen la síntesis de bloques de construcción de molécula de pre ADN tal como el metotrexato (Abitrexate®), el fluorouracilo (Adrucil®), la hidroxicarbamida (Hydrea®) y la mercaptopurina (Purinetol®). Es decir, por ejemplo, un co-agente seleccionados de la categoría de fármacos que dañan directamente el ADN en el núcleo la célula tal como el cisplatino (Platinol®) y los antibióticos - daunorrubicina (Cerubidine®), doxorrubicina (Adriamycin®), y etoposida (VePesid®). Es decir, por ejemplo, un co agente seleccionado de la categoría de fármacos que efectúan la síntesis o rotura de los husos mitóticos tales como la Vinblastina (Velban®), Vincristina (Oncovin®) y Pacitaxel (Taxol®).
De acuerdo con otra realización de la invención, los compuestos de acuerdo con la invención y las formulaciones farmacéuticas de los mismos pueden administrarse en combinación con agentes dirigidos a las proteínas de la superficie celular tales como transferencia de genes de la cadena de receptores de citoquinas y administración de citotoxina orientada al receptor.
De acuerdo con otra realización de la invención, los compuestos de acuerdo con la invención y las formulaciones farmacéuticas de los mismos pueden administrarse en combinación con la terapia de radiación.
La invención abarca la administración de un compuesto de acuerdo con la invención o de una formulación farmacéutica del mismo, en la cual el compuesto de acuerdo con la invención o la formulación farmacéutica del mismo es administrado a un individuo antes de, simultáneamente o secuencialmente con otros regímenes terapéuticos o co-agentes útiles en el tratamiento de los cánceres (por ejemplo, varios regímenes de fármacos), en una cantidad terapéuticamente efectiva. Los compuestos de acuerdo con la invención o las formulaciones farmacéuticas de los mismos que son administradas simultáneamente con dichos co-agentes pueden ser administrados en la misma o en diferente composición(es) y por la misma o por diferentes rutas de administración.
En otra realización particular, se contemplan los compuestos para la utilización en el tratamiento de los cánceres en donde la administración de un compuesto de acuerdo con la invención se lleva a cabo típicamente durante o después de la quimioterapia, la hormonoterapia o la radioterapia.
En otra realización particular, se contemplan los compuestos de la invención para la utilización en el tratamiento de los cánceres en donde la administración de un compuesto de acuerdo con la invención se lleva a cabo típicamente después de un régimen de quimioterapia, de hormonoterapia o de radioterapia en los momentos en los que el tejido del tumor estará respondiendo a los asaltos tóxicos mediante la inducción de angiogénesis para recuperarse mediante la provisión de un suministro de sangre y de nutrientes al tejido del tumor.
En otra realización, la administración del compuesto de acuerdo con la invención se realiza después de la cirugía donde han eliminado tumores sólidos como una profilaxis contra las metástasis.
13
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09171466A EP2305679A1 (en) | 2009-09-28 | 2009-09-28 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
EP09171466 | 2009-09-28 | ||
PCT/IB2010/054329 WO2011036651A1 (en) | 2009-09-28 | 2010-09-27 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2644857T3 true ES2644857T3 (es) | 2017-11-30 |
Family
ID=41347804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10782688.5T Active ES2644857T3 (es) | 2009-09-28 | 2010-09-27 | Derivados de pirazolindiona como inhibidores de la NADPH |
Country Status (24)
Country | Link |
---|---|
US (1) | US9394306B2 (es) |
EP (2) | EP2305679A1 (es) |
JP (1) | JP5707406B2 (es) |
KR (1) | KR101791273B1 (es) |
CN (1) | CN102686590B (es) |
AU (1) | AU2010299487B2 (es) |
BR (1) | BR112012004208A2 (es) |
CA (1) | CA2770278C (es) |
CY (1) | CY1119780T1 (es) |
DK (1) | DK2483271T3 (es) |
ES (1) | ES2644857T3 (es) |
HK (1) | HK1171748A1 (es) |
HR (1) | HRP20171638T1 (es) |
HU (1) | HUE035058T2 (es) |
IL (1) | IL218814A0 (es) |
LT (1) | LT2483271T (es) |
ME (1) | ME03040B (es) |
NO (1) | NO2483271T3 (es) |
PL (1) | PL2483271T3 (es) |
PT (1) | PT2483271T (es) |
RS (1) | RS56542B1 (es) |
RU (1) | RU2569855C2 (es) |
SI (1) | SI2483271T1 (es) |
WO (1) | WO2011036651A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
WO2013078261A1 (en) | 2011-11-22 | 2013-05-30 | The University Of Maryland, Baltimore | Treatment of muscular conditions and muscular dystrophies |
JP2015509969A (ja) * | 2012-03-16 | 2015-04-02 | グルソックス・バイオテック・アーベー | Nox4阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用 |
CN104918616A (zh) | 2012-10-24 | 2015-09-16 | 格卢科克斯生物科技有限公司 | 用于治疗与烟酰胺腺嘌呤二核苷酸磷酸氧化酶相关的病况的三嗪衍生物 |
EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
US10173988B2 (en) | 2015-02-16 | 2019-01-08 | Glucox Biotech Ab | N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine |
EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
GB2587457B (en) | 2017-08-04 | 2022-06-01 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
KR20210135241A (ko) | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
WO2023101418A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931407A (en) | 1973-03-01 | 1976-01-06 | American Hoechst Corporation | Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent |
DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
DE19518082A1 (de) | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one |
US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
AU6320998A (en) | 1997-02-21 | 1998-09-09 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
JP4196678B2 (ja) | 2001-04-26 | 2008-12-17 | 味の素株式会社 | 複素環化合物 |
KR20040097375A (ko) | 2002-04-23 | 2004-11-17 | 시오노기 앤드 컴파니, 리미티드 | 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제 |
AU2003267980A1 (en) | 2002-07-03 | 2004-01-23 | Janssen Pharmaceutica, N.V. | Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders |
WO2004075884A1 (en) | 2003-02-28 | 2004-09-10 | Howard Florey Institute Of Experimental Physiology And Medicine | Therapeutic compositions |
JPWO2004089412A1 (ja) | 2003-04-08 | 2006-07-06 | 三菱ウェルファーマ株式会社 | 特異的nad(p)hオキシダーゼ抑制剤 |
TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
RU2266906C1 (ru) * | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
KR20070060156A (ko) | 2004-10-04 | 2007-06-12 | 미리어드 제네틱스, 인크. | 알츠하이머병 치료용 화합물 |
FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
US20070014739A1 (en) | 2005-07-14 | 2007-01-18 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
KR20080110886A (ko) | 2006-04-04 | 2008-12-19 | 미리어드 제네틱스, 인크. | 질병 및 장애용 화합물 |
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
TW200930713A (en) | 2007-12-03 | 2009-07-16 | Takeda Pharmaceutical | Nitrogen-containing heterocyclic compound and use thereof |
FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
-
2009
- 2009-09-28 EP EP09171466A patent/EP2305679A1/en not_active Withdrawn
-
2010
- 2010-09-27 WO PCT/IB2010/054329 patent/WO2011036651A1/en active Application Filing
- 2010-09-27 ME MEP-2017-258A patent/ME03040B/me unknown
- 2010-09-27 EP EP10782688.5A patent/EP2483271B1/en active Active
- 2010-09-27 NO NO10782688A patent/NO2483271T3/no unknown
- 2010-09-27 BR BR112012004208A patent/BR112012004208A2/pt not_active Application Discontinuation
- 2010-09-27 RU RU2012117796/04A patent/RU2569855C2/ru not_active IP Right Cessation
- 2010-09-27 ES ES10782688.5T patent/ES2644857T3/es active Active
- 2010-09-27 RS RS20171071A patent/RS56542B1/sr unknown
- 2010-09-27 CA CA2770278A patent/CA2770278C/en not_active Expired - Fee Related
- 2010-09-27 LT LTEP10782688.5T patent/LT2483271T/lt unknown
- 2010-09-27 US US13/394,904 patent/US9394306B2/en not_active Expired - Fee Related
- 2010-09-27 DK DK10782688.5T patent/DK2483271T3/da active
- 2010-09-27 JP JP2012530402A patent/JP5707406B2/ja not_active Expired - Fee Related
- 2010-09-27 KR KR1020127007664A patent/KR101791273B1/ko active IP Right Grant
- 2010-09-27 HU HUE10782688A patent/HUE035058T2/en unknown
- 2010-09-27 CN CN201080041718.5A patent/CN102686590B/zh not_active Expired - Fee Related
- 2010-09-27 AU AU2010299487A patent/AU2010299487B2/en not_active Ceased
- 2010-09-27 SI SI201031580T patent/SI2483271T1/en unknown
- 2010-09-27 PL PL10782688T patent/PL2483271T3/pl unknown
- 2010-09-27 PT PT107826885T patent/PT2483271T/pt unknown
-
2012
- 2012-03-25 IL IL218814A patent/IL218814A0/en unknown
- 2012-12-05 HK HK12112534.4A patent/HK1171748A1/zh not_active IP Right Cessation
-
2017
- 2017-10-26 HR HRP20171638TT patent/HRP20171638T1/hr unknown
- 2017-11-03 CY CY20171101161T patent/CY1119780T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HK1171748A1 (zh) | 2013-04-05 |
KR101791273B1 (ko) | 2017-10-27 |
CA2770278A1 (en) | 2011-03-31 |
CN102686590B (zh) | 2015-09-16 |
PL2483271T3 (pl) | 2018-02-28 |
JP5707406B2 (ja) | 2015-04-30 |
RU2569855C2 (ru) | 2015-11-27 |
PT2483271T (pt) | 2017-11-15 |
HUE035058T2 (en) | 2018-05-02 |
IL218814A0 (en) | 2012-06-28 |
BR112012004208A2 (pt) | 2016-03-29 |
US20120172352A1 (en) | 2012-07-05 |
DK2483271T3 (da) | 2017-11-27 |
CA2770278C (en) | 2018-08-14 |
EP2483271A1 (en) | 2012-08-08 |
LT2483271T (lt) | 2017-11-10 |
CY1119780T1 (el) | 2018-09-05 |
US9394306B2 (en) | 2016-07-19 |
RS56542B1 (sr) | 2018-02-28 |
EP2305679A1 (en) | 2011-04-06 |
RU2012117796A (ru) | 2013-11-20 |
SI2483271T1 (en) | 2018-01-31 |
NO2483271T3 (es) | 2018-01-13 |
CN102686590A (zh) | 2012-09-19 |
ME03040B (me) | 2018-10-20 |
KR20120090998A (ko) | 2012-08-17 |
AU2010299487A1 (en) | 2012-03-29 |
JP2013505930A (ja) | 2013-02-21 |
WO2011036651A1 (en) | 2011-03-31 |
EP2483271B1 (en) | 2017-08-16 |
HRP20171638T1 (hr) | 2017-12-01 |
AU2010299487B2 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2644857T3 (es) | Derivados de pirazolindiona como inhibidores de la NADPH | |
CN110621316B (zh) | 用ehmt2抑制剂进行的组合疗法 | |
Jaroch et al. | Combretastatins: in vitro structure-activity relationship, mode of action and current clinical status | |
KR102456088B1 (ko) | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 | |
ES2705698T3 (es) | Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib | |
KR102427777B1 (ko) | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 | |
ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
ES2374828T3 (es) | Combinaciones de agentes terapéuticos para el tratamiento del cáncer. | |
JP5345842B2 (ja) | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ | |
CN105764501A (zh) | 改善比生群治疗效益的组合物 | |
ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
US20210060039A1 (en) | Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof | |
ES2610931T3 (es) | Terapia de combinación | |
JP2019523277A (ja) | 血液癌の併用療法 | |
US10080807B2 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin C | |
ES2428358T3 (es) | Terapia de combinación | |
WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
EP3126356A1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
US20130274198A1 (en) | Treating muc1-expressing cancers with combination therapies | |
Gilliam et al. | Emerging biological therapies for pancreatic carcinoma | |
US20190117663A1 (en) | Compositions and methods for treating cancer | |
TW202131917A (zh) | 併用醫藥 | |
ES2415907T3 (es) | Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos | |
ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico | |
Angelini et al. | Antipsychotics reverse p-glycoprotein-mediated doxorubicin resistance in human uterine sarcoma MES-SA/Dx5 cells: A novel approach to cancer chemotherapy |